4′-Methoxy-2-styrylchromone a novel microtubule-stabilizing antimitotic agent

Biochemical Pharmacology

Volumn 75, Issue 4, 2008, Pages 826-835

  Marinho, Joana ^a   Pedro, Madalena ^a,b   Pinto, Diana C G A ^c   Silva, Artur M S ^c   Cavaleiro, José A S ^c   Sunkel, Claudio E ^d   Nascimento, Maria São José ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

2 Styrylchromone; Antimitotic drugs; Cancer chemotherapy; Cell cycle; Mitosis; Tubulin

Indexed keywords

4 METHOXY 2 STYRYLCHROMONE; ANTIMITOTIC AGENT; PACLITAXEL; TUBULIN; UNCLASSIFIED DRUG; 4' METHOXY 2 STYRYLCHROMONE; 4'-METHOXY-2-STYRYLCHROMONE; CHROMONE DERIVATIVE; STYRENE DERIVATIVE; TUBULIN MODULATOR;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL STRUCTURE; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE; MICROTUBULE; MITOSIS; POLYMERIZATION; PRIORITY JOURNAL; PROMETAPHASE; TUMOR CELL; CELL CYCLE; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; FLUORESCENCE MICROSCOPY; MITOSIS INDEX; TUMOR CELL LINE;

CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; HUMANS; LYMPHOCYTES; MICROSCOPY, FLUORESCENCE; MICROTUBULES; MITOTIC INDEX; MOLECULAR STRUCTURE; STYRENES; TUBULIN MODULATORS;

EID: 38749147746     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.10.014     Document Type: Article

References (24)

1. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 4 (2004) 253-265
2. Zhou J., and Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 5 (2005) 65-71
3. Miglarese M.R., and Carlson R.O. Development of new cancer therapeutic agents targeting mitosis. Expert Opin Investig Drugs 15 (2006) 1411-1425
4. Gottesman M.M. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 53 (1993) 747-754
5. Hari M., Wang Y., Veeraraghavan S., and Cabral F. Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol Cancer Ther 2 (2003) 597-605
6. Horwitz S.B., Cohen D., Rao S., Ringel I., Shen H.J., and Yang C.P. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr (1993) 55-61
7. Liscovitch M., and Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5 (2002) 349-355
8. Markman M. Managing taxane toxicities. Support Care Cancer 11 (2003) 144-147
9. Rowinsky E.K., Eisenhauer E.A., Chaudhry V., Arbuck S.G., and Donehower R.C. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20 (1993) 1-15
10. Pinto D.C., Silva A.M., Almeida L.M., Cavaleiro J.A., Lévai A., and Patonay T. Synthesis of 4-aryl-3-(2-chromonyl)-2-pyrazolines by the 1:3-dipolar cycloaddition of 2-styrylchromones with diazomethane. J Heterocycl Chem 35 (1998) 217-224
11. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82 (1990) 1107-1112
12. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83 (1991) 757-766
13. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
14. Gonzalez M.J., Nascimento M.S., Cidade H.M., Pinto M.M., Kijjoa A., Anantachoke C., et al. Immunomodulatory activity of xanthones from Calophyllum teysmannii var. inuphylloide. Planta Med 65 (1999) 368-371
15. Hood K.A., West L.M., Rouwe B., Northcote P.T., Berridge M.V., Wakefield S.J., et al. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Cancer Res 62 (2002) 3356-3360
16. Wilson L., and Jordan M.A. New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies. J Chemother 16 Suppl. 4 (2004) 83-85
17. Schiff P.B., and Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77 (1980) 1561-1565
18. Jordan M.A., Toso R.J., Thrower D., and Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90 (1993) 9552-9556
19. Jordan M.A., Wendell K., Gardiner S., Derry W.B., Copp H., and Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56 (1996) 816-825
20. Schiff P.B., Fant J., and Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 277 (1979) 665-667
21. ter Haar E., Kowalski R.J., Hamel E., Lin C.M., Longley R.E., Gunasekera S.P., et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 35 (1996) 243-250
22. Lindel T., Jensen P.R., Fenical W., Long B.H., Casazza A.M., Carboni J.M., et al. Eleutherobin, a new cytotoxin that mimics paclitaxel (taxol) by stabilizing microtubules. J Am Chem Soc 119 (1997) 8744-8745
23. Long B.H., Carboni J.M., Wasserman A.J., Cornell L.A., Casazza A.M., Jensen P.R., et al. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). Cancer Res 58 (1998) 1111-1115
24. Mooberry S.L., Tien G., Hernandez A.H., Plubrukarn A., and Davidson B.S. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res 59 (1999) 653-660